Hélène Charlotte Bertrand

Dr. Hélène Charlotte Bertrand

Sorbonne University, Paris, Île-de-France, France
orcid
Associate Professor, Sorbonne Université

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2008 in Biochimie
Verified
Journal Article
Closed access
DMDavid Monchaud
David Monchaud
CAClémence Allain
Clémence Allain
Hélène Charlotte BertrandHélène Charlotte Bertrand
Hélène Charlotte Bertrand
NSN. Smargiasso
N. Smargiasso
FRF. Rosu
F. Rosu
MTM.-P. Teulade-Fichou
M.-P. Teulade-Fichou

1 November 2014 in Chemistry & Biology
Verified
Journal Article
Open access
DEDaniel A. East
Daniel A. East
FFFrancesca Fagiani
Francesca Fagiani
JCJames Crosby
James Crosby
NGNikolaos D. Georgakopoulos
Nikolaos D. Georgakopoulos
Hélène Charlotte BertrandHélène Charlotte Bertrand
Hélène Charlotte Bertrand
MCMichelangelo Campanella
Michelangelo Campanella
Mitophagy is central to mitochondrial and cellular homeostasis and operates via the PINK1/Parkin pathway targeting mitochondria devoid of membrane potential (ΔΨm) to autophagosomes. Although mitophagy is recognized as a fundamental cellular process, selective pharmacologic modulators of mitophagy are almost nonexistent. We developed a compound that increases the expression and signaling of the autophagic adaptor molecule P62/SQSTM1 and forces mitochondria into autophagy. The compound, P62-mediated mitophagy inducer (PMI), activates mitophagy without recruiting Parkin or collapsing ΔΨm and retains activity in cells devoid of a fully functional PINK1/Parkin pathway. PMI drives mitochondria to a process of quality control without compromising the bio-energetic competence of the whole network while exposing just those organelles to be recycled. Thus, PMI circumvents the toxicity and some of the nonspecific effects associated with the abrupt dissipation of ΔΨm by ionophores routinely used to induce mitophagy and represents a prototype pharmacological tool to investigate the molecular mechanisms of mitophagy.

1 January 2012 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
RHRowena Hancock
Rowena Hancock
Hélène Charlotte BertrandHélène Charlotte Bertrand
Hélène Charlotte Bertrand
TTTadayuki Tsujita
Tadayuki Tsujita
SNShama Naz
Shama Naz
AEAyman El-Bakry
Ayman El-Bakry
GWGeoff Wells
Geoff Wells

5 July 2007 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
Hélène Charlotte BertrandHélène Charlotte Bertrand
Hélène Charlotte Bertrand
DMDavid Monchaud
David Monchaud
ACAnne De Cian
Anne De Cian
RGRégis Guillot
Régis Guillot
JMJean-louis Mergny
Jean-louis Mergny
MTMarie-Paule Teulade-Fichou
Marie-Paule Teulade-Fichou
A family of terpyridine metallo-organic complexes has been designed and its recognition properties of G-quadruplex-DNA investigated. The series combines easy synthetic access and good affinity–selectivity ratio for quadruplex-DNA. Our study also highlights that the geometry of the metal center strongly governs the ability of the compounds to discriminate quadruplex from duplex-DNA.

2 March 2017 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
FKFiona Kerr
Fiona Kerr
OSOyinkan Sofola-Adesakin
Oyinkan Sofola-Adesakin
DIDobril K Ivanov
Dobril K Ivanov
JGJemma Gatliff
Jemma Gatliff
BPBeatriz Gomez Perez-Nievas
Beatriz Gomez Perez-Nievas
LPLinda Partridge
Linda Partridge
Nrf2, a transcriptional activator of cell protection genes, is an attractive therapeutic target for the prevention of neurodegenerative diseases, including Alzheimer’s disease (AD). Current Nrf2 activators, however, may exert toxicity and pathway over-activation can induce detrimental effects. An understanding of the mechanisms mediating Nrf2 inhibition in neurodegenerative conditions may therefore direct the design of drugs targeted for the prevention of these diseases with minimal side-effects. Our study provides the first in vivo evidence that specific inhibition of Keap1, a negative regulator of Nrf2, can prevent neuronal toxicity in response to the AD-initiating Aβ42 peptide, in correlation with Nrf2 activation. Comparatively, lithium, an inhibitor of the Nrf2 suppressor GSK-3, prevented Aβ42 toxicity by mechanisms independent of Nrf2. A new direct inhibitor of the Keap1-Nrf2 binding domain also prevented synaptotoxicity mediated by naturally-derived Aβ oligomers in mouse cortical neurons. Overall, our findings highlight Keap1 specifically as an efficient target for the re-activation of Nrf2 in AD, and support the further investigation of direct Keap1 inhibitors for the prevention of neurodegeneration in vivo. As our population ages the incidence of neurodegenerative diseases, including Alzheimer’s disease (AD), is predicted to increase dramatically. Despite providing important symptomatic relief, existing treatments for such conditions do not slow-down disease progression, and this will cause an overwhelming future burden on our healthcare system and immense suffering for many more patients and their families. Nrf2 is a gene that normally protects cells from stressful conditions. Although we don’t know why, Nrf2 is reduced in the brains of AD patients and this may explain the increased susceptibility of neurons to damage in neurodegenerative diseases. Our research, using a fruit fly model, identifies Keap1, a negative regulator of Nrf2, as a valid target for the rescue of AD-related Nrf2 defects and the subsequent prevention of neuronal degeneration. Moreover, we show that a new compound, which directly blocks the binding between Nrf2 and Keap1, can prevent toxicity of the AD-initiating Aβ peptide in mouse neurons. Hence, our study provides strong evidence that direct Keap1-Nrf2 disruptors can specifically target the defects in Nrf2 activity observed in neurodegenerative diseases, and supports the further development of such compounds as potential new drugs to prevent neuronal decline AD and other neurodegenerative conditions.

14 September 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Hélène Charlotte BertrandHélène Charlotte Bertrand
Hélène Charlotte Bertrand
MSMarjolein Schaap
Marjolein Schaap
LBLiam Baird
Liam Baird
NGNikolaos D. Georgakopoulos
Nikolaos D. Georgakopoulos
AFAdrian Fowkes
Adrian Fowkes
GWGeoff Wells
Geoff Wells